Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Generalised Lipodystrophy Clear all
Recruiting No phase listed Observational
View directory record Official record
Conditions
Generalised Lipodystrophy, Partial Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Amryt Pharma
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 11:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Lipodystrophy
Interventions
Not listed
Lead sponsor
PatientCrossroads
Industry
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced May 21, 2026, 11:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced May 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Placebo, Low-Dose REGN4461, High-dose REGN4461
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 21, 2026, 11:24 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Interventions
Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 21, 2026, 11:24 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Lipodystrophy, Diabetes, Hyperlipidemia
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 98 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, TT vaccine booster
Drug · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced May 21, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 21, 2026, 11:24 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Mibavademab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 11:24 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
mibavademab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 11:24 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced May 21, 2026, 11:24 PM EDT